Introduction {#sec1-1}
============

In 2012, a total of 1.7 million women developed breast cancer globally and a staggering 6.3 million women who had been detected to have this disease in the preceding 5 years were alive.\[[@ref1]\] In the USA, the 5-year overall survival (OS) for breast cancer has increased from 75% in 1970s to almost 89%, presently.\[[@ref2]\] Unfortunately, this is not replicated in developing countries. For instance, the corresponding figure is about 60% for India.

The magnitude of the problem shall continue to increase, the Indian Council for Medical Research Cancer Atlas project confirming that, in 2008, that there was a 26.6% increase in the total number of cancer cases to be registered from the five cities of Bengaluru, Chennai, Delhi, Bhopal, and Mumbai.\[[@ref3][@ref4]\]

The hospital-based registry data of 2008 from the largest cancer center in India, reported on 2001 new patients of breast cancers. Estrogen receptor (ER) and/or progesterone receptor (PR) expression was positive in tumors of 1025 (51.2%) patients. Human epidermal receptor 2 (HER2) 3+ expression by immunohistochemistry (IHC) was found in 335 (16.7%) and HER2 2+ in 163 (8.1%). The triple negative phenotype was found in 596 (29.8%) patients. An estimated 441 patients were eligible to receive HER2-targeted therapy based on their HER2 status. Of these 38 (8.6%) patients received some form of HER2-targeted therapy; twenty patients (4.5%) as part of ongoing clinical trials and 18 (4.1%) as part of routine care.\[[@ref5]\]

The cost of therapy is, therefore, a major limiting factor. To improve the outcome of breast cancer in India, we adapted the FinHer schedule in HER2 positive breast cancer patients who had successfully undergone potentially curative R0 resection and were unwilling to accept the standard 1 year trastuzumab therapy. They were followed up prospectively, and the analysis of this data is being presented here.

Materials and Methods {#sec1-2}
=====================

Patients with HER2 positive breast cancer who had undergone potentially curative surgery and were given adjuvant short course trastuzumab-chemotherapy combination were followed up prospectively. Detailed history, examination, operative details, and histopathological reports were recorded. HER2 expression was determined by IHC and/or fluorescence *in situ* hybridization (FISH) and interpreted using standard recommendations.\[[@ref5][@ref7]\]

Part one of the systemic therapy consisted of three cycles of docetaxel (80--100 mg/m^2^ as a 1 h intravenous infusion on day 1 of each 21-day cycle). Simultaneously, nine trastuzumab infusions were administered at weekly intervals, the first infusion being given on day 1 before the first docetaxel.\[[@ref6]\] The first dose of trastuzumab (4 mg/kg) was administered over 90 min, and the subsequent doses (2 mg/kg) were administered over 30--60 min infusions. Part two of the systemic therapy included three cycles of intravenous (fluorouracil 500 mg/m^2^, epirubicin 90 mg/m^2^, and cyclophosphamide 500 mg/m^2^ \[FEC\]) also administered on day 1 of each 21-day cycle. No trastuzumab was given during FEC administration or after chemotherapy. Additional supportive care was given as necessary for each patient (antiemetics, growth factors, etc.)

Regular monitoring and blood tests were carried out as per published guidelines and doses reduced, omitted, or postponed as required. Once the systemic chemotherapy was concluded, patients were given appropriate radiation therapy and endocrine therapy if applicable.

Patients were followed up at regular intervals. In case of clinical suspicion of recurrence of breast cancer, appropriate investigative studies were carried out to document the same. Patients were given additional cancer-directed therapy on a case to case basis as required. Follow-up was continued in all patients and status recorded as on April 5, 2016.

Results {#sec1-3}
=======

A total of 21 patients with HER2 positive breast cancer who received adjuvant short course trastuzumab combination chemotherapy were evaluated from July 2009 to April 2016. Their age ranged from 40 to 72 years with a median of 62 years. This included 4 premenopausal women and 17 postmenopausal ladies. Four of them had undergone breast conservative surgery, and the remaining 17 had opted for modified radical mastectomy. The surgery was done by an oncosurgeon in 17 of the 21 cases.

Histology confirmed invasive ductal carcinoma in all the cases. It was reported as Grade 1 in one patient, Grade 2 in 11 and Grade 3 in the remaining nine patients. The size of the primary tumor was ≤2 cm tumor in three patients, 2--5 cm in 17 cases and \>5 cm in one patient. Of the total 21 patients, axillary lymph node (LN) involvement was seen in 16 (76%), more than 3 LN were positive in 14 patients. Lymphovascular emboli positivity in 11 and perineural invasion in 5. Three patients had a significant component of ductal carcinoma *in situ*.

HER2 was 3+ on IHC in 19 patients and 2+ in two patients confirmed as positive on FISH. Of these 7 were expressing ER (6 of them also being PR positive). The majority were fit with 7 having comorbidities (6 HT, 4 DM, and 1 obesity).

Serious Adverse events included febrile neutropenia,\[[@ref2]\] port site infection,\[[@ref1]\] and hand-foot syndrome (HFS; 1). None of the patients required dose omission or discontinuation. Dose reduction was necessary in one patient (who had developed HFS). None of the patients experienced any cardiotoxicity.

Additional postoperative local treatment in the form of RT was given to 16 patients. All the hormone receptor positive patients received endocrine therapy following the completion of chemotherapy. This included tamoxifenin 4, anastrozole in 2, and letrozole in 1 patient.

For the group as a whole, the recurrence-free survival (RFS) ranged from 6 to 73 months with median not yet reached. RFS at 3 years was 71.1%.

Similarly, the OS ranged from 9 to 73 months with median still to be reached. OS at 3 years was 89.9%.

At the last follow-up (as of April 5, 2016), 15 patients remained cancer free and well, four patients had died due to recurrent, progressive breast cancer, and the other two were alive with recurrent disease. All six patients who had a recurrence or died with progressive disease were axillary LN positive with more than 3 LNs involved. Recurrence was noted within 8--30 months after the operation. The brain was the first site of metastatic disease in three out of 6 patients. One patient had local recurrence \[[Table 1](#T1){ref-type="table"}\].
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Discussion {#sec1-4}
==========

Breast cancer is a major and escalating problem for developing countries. Data from local registries in India that show that Globocan data are underestimating breast cancer incidence in India. The Indian Council of Medical Research population-based cancer registry of New Delhi shows the incidence to be 29.3/100,000 of the population in 1994--1995.\[[@ref8]\] Moreover, the Indian Cancer Society\'s Maharashtra population-based registry shows it to be 26.8 per 100,000 of the population in 2001.\[[@ref4]\] Both these figures are higher than the \<19.5 incidence per 100,000 population showed in Globocan 2002 data.\[[@ref9][@ref10]\]

In India, the age-adjusted incidence shows an increasing trend of 1.6% from Indian Cancer Society\'s Mumbai cancer registry (metro region) over a 15 years of period (1996--2010).\[[@ref1][@ref4]\] Moreover, the projected increase in India\'s urban population will be to \>550 million by 2030. Correspondingly, there will be a doubling of breast cancer burden from a mean annual figure of 1300 (in 2001--2005) to over 2500 (projected annual incidence for the period 2021--2025).

The incidence of HER2 positive cases comprises a significant portion of this tumor burden-- making up 25%--34%.\[[@ref5][@ref8]\] Such patients have a poor prognosis, requires expensive HER2 directed therapy saving lives.\[[@ref7]\] Unfortunately, its cost makes it applicable to \<5% of the eligible population.\[[@ref5]\] After endocrine therapy, the only other systemic treatment showing substantial benefit is targeting HER2 with trastuzumab. A recent Cochrane meta-analysis of 6 adjuvant and 2 neoadjuvant randomized controlled trials (RCTs-NSABP B-31, NCCTG N9831, BCIRG 006, HERA, FinHer, PACS-04, Buzdar, and NOAH), showed that mortality is reduced by about 33% and the risk of relapse is diminished by 40%.\[[@ref10]\] Recommended duration of adjuvant trastuzumab therapy has been 1 year. However, affordability and cost-effectiveness of 1 year therapy has been a concern, especially in Indian patients.

The FinHer trial showed that 9 weeks of trastuzumab is more effective than none at all (control), with no difference in cardiotoxicity or brain metastasis.\[[@ref11][@ref12]\] Of the 1010 women in FinHer, 232 were HER2 positive, and they were divided into two equal groups (116 each)-- one of them receiving short course 9 weeks trastuzumab. At a median follow-up of 62 months, there was no significant difference in distant disease-free survival (DFS) or OS between patients who received trastuzumab (*n* = 116) and those who did not (*n* = 116). At 5 years, trastuzumab-treated patients had a DFS rate of 83.3% and an OS rate of 91.3%. In patients who received chemotherapy alone, 5-year DFS and OS rates were 73% and 82.3%, respectively (hazard ratio \[HR\] for OS = 0.55; 95% confidence interval \[CI\], 0.27--1.11; *P* =0.094). However, DRFS of patients who received docetaxel, trastuzumab, and FEC was superior to that of patients who received docetaxel and FEC (HR0.32; 95% CI, 0.12--0.89; P. 029). Any recurrence was noted in 9.3% of patients treated with Docetaxel/FEC/trastuzumab versus 25.9% of Docetaxel/FEC-treated patients. Possible determinants for success in this regimen were the early administration of trastuzumab and sequencing of taxanes first before anthracyclines.\[[@ref13]\]

This attenuated duration of trastuzumab, therefore, became a beacon of hope for Indian patients with financial limitations.\[[@ref12]\] In a country, where \<10% of the population used to have a meaningful medical insurance and \<5% of eligible patients actually receive trastuzumab, the combination of 9 weekly trastuzumab concomitant with docetaxel followed by FEC may be affordable and effective option with minimal toxicity.

Icli *et al*. conducted a retrospective analysis comparing DFS in patients who received adjuvant herceptin for 9 weeks versus \>9 weeks. Investigators reviewed Turkish Ministry of Health records of 690HER2-positive breast cancer patients. Median follow-up was 22 months. A greater percentage of patients in the \>9-week cohort received either breast-conserving surgery (*P* = 0.015) or adjuvant radiotherapy (*P* = 0.001) compared with those in the 9-week cohort. A higher proportion of node-negative patients (*P* = 0.002) were observed in the 9-week cohort. At 2 years, DFS in patients who received herceptin for 9 weeks (*n* = 204) was 85.6% compared with 85.4% of patients who received herceptin for \>9 weeks (*n* = 486; unadjusted HR 0.934; 95% CI, 0.552--1.580, *P* = 0.28). Cardiac toxicity leading to interruption of herceptin therapy was reported in 0% of patients in the 9-week group and 3.3% of patients in the \>9-week group.\[[@ref14]\]

In the second retrospective analysis, Tonyali *et al*. compared results for 479 consecutive women who received adjuvant herceptin for 9 weeks (*n* = 181) or 52 weeks (*n* = 298) at 8 centers. The median duration of follow-up was 30 months. At baseline, the 52-week group had more high-risk patients who had received intensive adjuvant treatment than the 9-week group. Results at 36 months for DFS and OS were similar in the 2 groups. For 9 weeks versus 52 weeks, respectively, the DFS rate was 90% versus 85% (*P* = 0.132) and the OS rate was 96% versus 97% (*P* = 0.779). Recurrences were observed in 8.3% versus 11.7% and death occurred in 2.7% and 2% of patients treated for 9 weeks versus 52 weeks, respectively.\[[@ref15]\]

Sendur *et al*. retrospectively analyzed patients with HER2-positive, node-positive breast cancer who received adjuvant herceptin for 9 weeks (*n* = 155) and 52 weeks (*n* = 116).16 Median follow-up was 34 (4--95) months, there was no difference in DFS (*P* = 0.76) and OS (*P* = 0.99) at year 1, 3 and 5.\[[@ref16]\]

Reports of survival rates Indian patients with HER2 positive breast cancer with or without adjuvant trastuzumab therapy are sparse.

In a study, reporting outcome of breast cancer patients from Eastern India, 5 years survival of HER2 positive patients was only 36.8%. Adjuvant therapy in these patients did not incorporate trastuzumab (2011).\[[@ref17]\]

DFS of 46.1% at median follow-up of 40 months was noted in HER2 positive patients treated at a center in Bengaluru, India (2010).\[[@ref18]\]

Our retrospective study of small number of Indian patients reveals the experience of adjuvant short course trastuzumab/docetaxel/FEC combination (FinHer like) therapy in breast cancer. Six out of 21 patients developed recurrence after trastuzumab-based adjuvant therapy. All these patients who developed recurrence in spite of incorporation of trastuzumab in the adjuvant regimen however, had higher risk features like more than 3 axillary LN positive. This recurrence rate seems to be higher than expected as per the efficacy rates of adjuvant trastuzumab reported in various global trials, however, may be better than those reported for Indian patients with HER2-positive breast cancer without anti-HER2 therapy.

Trials evaluating shorter duration of trastuzumab therapy have failed to confirm the efficacy as against standard 1 year therapy. The PHARE trial was a Phase 3, randomized, noninferiority study comparing the efficacy and safety of 6-month trastuzumab to 12-month trastuzumab in patients with HER2-positive early breast cancer (*n* = 1690 patients in each arm).\[[@ref19]\] The study failed to show that 2-year DFS, the primary endpoint, was noninferior for patients who received trastuzumab for 6 months compared with 12 months. At a median follow-up of 42.5 months, the HR for 2-year DFS for 6 months vs12 months of trastuzumab, the primary endpoint, was 1.28 with a 95% CI of 1.05--1.56 (*P* = 0.29). The 2-year DFS rate was 93.8% in the 12-month group and 91.1% in the 6-month group. The HR for DFS in the subgroup of ER-positive (*n* = 1968; HR 1.23; 95% CI, 0.92--1.65) and ER-negative (*n* = 1,412; HR 1.34; 95%CI, 1.02--1.76) patients also favored 12 months of trastuzumab treatment versus 6 months of treatment.

Conclusion {#sec1-5}
==========

Adjuvant trastuzumab saves lives and should be offered to all patients with HER2 positive breast cancer (node-positive and node-negative with a tumor size exceeding 1 cm) who are planned for adjuvant chemotherapy. One year remains the standard duration of adjuvant trastuzumab therapy recommended. Regimens of shorter duration trastuzumab like FinHer, offered in view of economic constraints in countries like India may not be able to achieve globally comparable cure rates in early breast cancer especially with higher risk factors such as more than 3 LN positive. The results from SOLD, Short-HER, and PERSEPHONE are eagerly awaited with the expectation that they will confirm the FinHer data for the efficacy of short duration trastuzumab therapy.
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